2023 World Conference on Lung Cancer (Posters)-P2.09. A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study)

P2.09. A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study) - PDF(Slides)

Back to course

Pdf Summary

The study examined the real-world efficacy and safety of first-line osimertinib treatment in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor that has shown superior efficacy compared to other first-generation inhibitors. The study enrolled patients who received first-line osimertinib treatment between September 2018 and August 2020.<br /><br />The primary endpoint of the study was progression-free survival (PFS) with osimertinib treatment. The study found that first-line osimertinib showed good effectiveness in clinical practice, consistent with previous trial results. Patients with exon 19 deletion mutations had significantly better PFS and overall survival (OS) than those with exon 21 L858R point mutations.<br /><br />The study also examined the progression patterns of the disease when RECIST progressive disease (PD) was encountered with osimertinib treatment. The progression patterns were described as CNS-only in 10.8% of patients, oligo-progression in 45.4% of patients, and multiple organ-progressions in 43.9% of patients. Notably, 56.7% of patients were asymptomatic at the time of RECIST PD.<br /><br />Furthermore, the study evaluated the post-progression treatments and outcomes. It was found that 47.4% of patients continued to receive osimertinib beyond RECIST PD. However, survival after RECIST PD in the clinically stable population was worse in the osimertinib continuation group compared to the osimertinib discontinuation group.<br /><br />Overall, this real-world observational study in a Japanese population confirmed the efficacy and safety of first-line osimertinib treatment in EGFR mutation-positive NSCLC. It also provided insights into the progression patterns and post-progression outcomes in patients receiving osimertinib.

Asset Subtitle

Kageaki Watanabe

Meta Tag

Speaker Kageaki Watanabe

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

osimertinib

EGFR mutation-positive non-small cell lung cancer

efficacy

safety

first-line treatment

progression-free survival

exon 19 deletion mutations

exon 21 L858R point mutations

progression patterns

post-progression treatments